Neeraj Gupta

4.9k total citations
156 papers, 2.5k citations indexed

About

Neeraj Gupta is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Neeraj Gupta has authored 156 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Molecular Biology, 67 papers in Hematology and 46 papers in Genetics. Recurrent topics in Neeraj Gupta's work include Multiple Myeloma Research and Treatments (50 papers), Chronic Lymphocytic Leukemia Research (45 papers) and Protein Degradation and Inhibitors (39 papers). Neeraj Gupta is often cited by papers focused on Multiple Myeloma Research and Treatments (50 papers), Chronic Lymphocytic Leukemia Research (45 papers) and Protein Degradation and Inhibitors (39 papers). Neeraj Gupta collaborates with scholars based in United States, India and Canada. Neeraj Gupta's co-authors include Karthik Venkatakrishnan, Deborah Berg, Alessandra Di Bacco, Michael J. Hanley, Anil Agarwal, Ai-Min Hui, Shaji Kumar, Ai‐Min Hui, Paul G. Richardson and Guohui Liu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Neeraj Gupta

140 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neeraj Gupta United States	28	1.6k	1.3k	771	382	271	156	2.5k
Susanna Jacobus United States	24	1.3k 0.8×	1.5k 1.2×	1.2k 1.6×	237 0.6×	431 1.6×	59	2.8k
Donna Weber United States	23	1.5k 0.9×	1.8k 1.3×	1.2k 1.5×	378 1.0×	181 0.7×	79	2.7k
Wilson I. Gonsalves United States	33	2.0k 1.3×	1.8k 1.4×	1.2k 1.5×	696 1.8×	188 0.7×	236	3.4k
David A. Cairns United Kingdom	28	1.4k 0.9×	817 0.6×	650 0.8×	137 0.4×	278 1.0×	131	2.7k
Edward N. Libby United States	22	1.1k 0.7×	1.2k 0.9×	1.1k 1.4×	268 0.7×	92 0.3×	87	2.5k
Jae Hoon Lee South Korea	27	851 0.5×	1.2k 0.9×	1.0k 1.3×	570 1.5×	378 1.4×	162	2.4k
Martha Arellano United States	27	2.0k 1.3×	2.6k 2.0×	848 1.1×	720 1.9×	187 0.7×	119	4.4k
Michel A. Duchosal Switzerland	25	479 0.3×	620 0.5×	528 0.7×	411 1.1×	216 0.8×	69	2.2k
William J. Edenfield United States	19	674 0.4×	661 0.5×	783 1.0×	394 1.0×	741 2.7×	101	2.1k
Hugo F. Fernández United States	35	1.6k 1.0×	3.6k 2.7×	878 1.1×	755 2.0×	181 0.7×	172	4.9k

Countries citing papers authored by Neeraj Gupta

Since Specialization

Citations

This map shows the geographic impact of Neeraj Gupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neeraj Gupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neeraj Gupta more than expected).

Fields of papers citing papers by Neeraj Gupta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neeraj Gupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neeraj Gupta. The network helps show where Neeraj Gupta may publish in the future.

Co-authorship network of co-authors of Neeraj Gupta

This figure shows the co-authorship network connecting the top 25 collaborators of Neeraj Gupta. A scholar is included among the top collaborators of Neeraj Gupta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neeraj Gupta. Neeraj Gupta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Cheryl, Scott Van Wart, Lili Yang, et al.. (2025). Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Modeling of Serum M‐Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma. Clinical and Translational Science. 18(7). e70296–e70296. 1 indexed citations

Otani, Yuki, Richard Labotka, Mark Rogge, et al.. (2024). Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2124–2136.

Hanley, Michael J., Steven Zhang, Robert Griffin, et al.. (2024). A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational New Drugs. 42(4). 343–352. 3 indexed citations

Hanley, Michael J., Paul M. Diderichsen, Benjamin E. Rich, et al.. (2023). Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study. Clinical Pharmacology & Therapeutics. 114(2). 413–422. 6 indexed citations

Kim, Richard D., Alexis D. Leal, Aparna R. Parikh, et al.. (2023). A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemotherapy and Pharmacology. 91(4). 291–300. 12 indexed citations

Burton, Jackson, Bilal Abuasal, Jamie N. Connarn, et al.. (2023). Future Opportunities in Drug Development: American Society for Clinical Pharmacology and Therapeutics Pharmacometrics and Pharmacokinetics Community Vision. Clinical Pharmacology & Therapeutics. 114(3). 507–510.

Hanley, Michael J., David Kerstein, Meera Tugnait, et al.. (2023). Brigatinib pharmacokinetics in patients with chronic hepatic impairment. Investigational New Drugs. 41(3). 402–410. 3 indexed citations

Gupta, Neeraj, Karen L. Reckamp, David Ross Camidge, et al.. (2022). Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC. Clinical and Translational Science. 15(5). 1143–1154. 5 indexed citations

Hanley, Michael J., M. D’Arcangelo, Enriqueta Felip, et al.. (2022). A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐Positive or ROS1‐Positive Solid Tumors. The Journal of Clinical Pharmacology. 63(5). 583–592. 2 indexed citations

10.

Shimizu, Toshio, Yasutoshi Kuboki, Chia‐Chi Lin, et al.. (2021). A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. Targeted Oncology. 17(1). 15–24. 5 indexed citations

11.

Gupta, Neeraj, Michael J. Hanley, David Kerstein, et al.. (2021). Effect of severe renal impairment on the pharmacokinetics of brigatinib. Investigational New Drugs. 39(5). 1306–1314. 7 indexed citations

12.

Gupta, Neeraj, Xiaohui Wang, Elliot Offman, et al.. (2020). Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. Clinical Pharmacokinetics. 60(2). 235–247. 15 indexed citations

13.

Ng, Terry L., Narayana I. Narasimhan, Neeraj Gupta, et al.. (2020). Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. Journal of Thoracic Oncology. 15(7). 1190–1199. 26 indexed citations

14.

Dimopoulos, Meletios Α., Sebastian Grosicki, W Wiktor-Jędrzejczak, et al.. (2018). All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. European Journal of Cancer. 106. 89–98. 27 indexed citations

15.

Sanchorawala, Vaishali, Giovanni Palladini, Vishal Kukreti, et al.. (2017). A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 130(5). 597–605. 101 indexed citations

16.

Gupta, Neeraj, et al.. (2015). Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients. Cancer Chemotherapy and Pharmacology. 76(3). 507–516. 24 indexed citations

17.

Agarwal, Anil, et al.. (2014). Tuberculosis of the hip in children. Indian Journal of Orthopaedics. 48(5). 463–469. 6 indexed citations

18.

Tannir, Nizar M., Christian Kollmannsberger, Marc S. Ernstoff, et al.. (2011). Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer. 47(18). 2706–2714. 24 indexed citations

19.

Goss, Glenwood, Ravi Salgia, Benjamin Besse, et al.. (2011). Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(8). 1418–1425. 54 indexed citations

20.

Dixit, Ramakant, et al.. (1999). Tracheostomy In Life Threatening Primary Spontaneous Pneumomediastinum In A 13 Year Male Child - A Case Report. Lung India. 17(2). 75.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact